Anebulo Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Richie Cunningham

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	18.3%
CEO görev süresi	1.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

CEO Tazminat Analizi

Richie Cunningham'un ücretlendirmesi Anebulo Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	US$2m	US$333k	-US$8m

Tazminat ve Piyasa: Richie 'nin toplam tazminatı ($USD 1.82M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.78K ).

Tazminat ve Kazançlar: Richie şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Richie Cunningham (53 yo)

1.1yrs

Görev süresi

US$1,819,383

Tazminat

Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Lawler	Founder & Chairman	4.6yrs	US$83.11k	46.27% $ 22.1m
Richard Cunningham	CEO & Director	1.1yrs	US$1.82m	Veri yok
Daniel George	Principal Accounting Officer	1.2yrs	US$194.25k	Veri yok
Kenneth Cundy	Chief Scientific Officer	2.5yrs	US$612.15k	0% $ 0

1.8yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: ANEB 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Lawler	Founder & Chairman	4.6yrs	US$83.11k	46.27% $ 22.1m
Richard Cunningham	CEO & Director	1.1yrs	US$1.82m	Veri yok
Bimal Shah	Independent Director	1.1yrs	US$124.53k	0% $ 0
Kenneth Lin	Lead Independent Director	3.8yrs	US$68.24k	0% $ 0
Areta Kupchyk	Independent Director	3.6yrs	US$76.87k	0% $ 0
Jason Aryeh	Independent Director	3.7yrs	US$83.24k	0% $ 0
Nathaniel Calloway	Independent Director	2.1yrs	US$67.26k	0% $ 0
Aron English	Independent Director	4.4yrs	US$66.87k	17.95% $ 8.6m
Andrew Monte	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Arjun Chanmugam	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ANEB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Anebulo Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

High number of new and inexperienced directors

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

New major risk - Share price stability

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

New major risk - Financial position

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Price target decreased to US$8.00

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors

Anebulo Pharmaceuticals, Inc. announced that it expects to receive $6.646748 million in funding from 22NW, LP and other investors

Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to launch private investment in public equity financing

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc.(NasdaqCM:ANEB) dropped from Russell Microcap Value Index

Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of A Phase 2 Clinical Trial and Provides Guidance on IND Submission

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Anebulo Pharmaceuticals reports FQ3 results

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş